U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3.C6H15NO3
Molecular Weight 287.3089
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TROLAMINE SALICYLATE

SMILES

OCCN(CCO)CCO.OC(=O)C1=C(O)C=CC=C1

InChI

InChIKey=UEVAMYPIMMOEFW-UHFFFAOYSA-N
InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.1207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H15NO3
Molecular Weight 149.1882
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.48 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

2008
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

2012
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
n = 43
Health Status: unhealthy
Condition: Acne vulgaris
Age Group: 23.05 ± 5.7 years
Sex: M+F
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Salicylate attenuates gentamicin-induced ototoxicity.
1999 Jul
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
2001
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.
2001
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Unraveling regulatory networks in plant defense using microarrays.
2001
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane.
2001 Apr
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.
2001 Feb
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals.
2001 Feb 1
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.
2001 Jan
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.
2001 Jan
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Manipulation of salicylate content in Arabidopsis thaliana by the expression of an engineered bacterial salicylate synthase.
2001 Jan
Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid.
2001 Jan
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.
2001 Jan
A nuclear casein kinase 2 activity is involved in early events of transcriptional activation induced by salicylic acid in tobacco.
2001 Jan
Pathogen-induced expression of plant ATP: citrate lyase.
2001 Jan 19
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae.
2001 Jan-Feb
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia.
2001 Jan-Feb
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.
2001 Mar
Interference by bilirubin in salicylate measurement.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Quantitative analysis of analgoantipyretics in dosage form using planar chromatography.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes.
2001 Mar 23
Use of methyl salicylate as a simulant to predict the percutaneous absorption of sulfur mustard.
2001 Mar-Apr
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.
2001 May
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle.
2001 May 1
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
2001 May 8
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:41 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:41 GMT 2023
Record UNII
H8O4040BHD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TROLAMINE SALICYLATE
MART.   USP   VANDF   WHO-DD  
Common Name English
TEA-SALICYLATE
INCI  
INCI  
Official Name English
TROLAMINE SALICYLATE [MART.]
Common Name English
TRIETHANOLAMINE SALICYLATE [MI]
Common Name English
NEOTAN W
Brand Name English
TEA-SALICYLATE [INCI]
Common Name English
TROLAMINE SALICYLATE [USP IMPURITY]
Common Name English
TRIETHANOLAMINE SALICYLATE [VANDF]
Common Name English
TROLAMINE SALICYLATE [USP MONOGRAPH]
Common Name English
TRIETHANOLAMINE SALICYLATE
MI   VANDF  
Systematic Name English
BENZOIC ACID, 2-HYDROXY-, COMPD. WITH 2,2',2''-NITRILOTRIS(ETHANOL) (1:1)
Common Name English
Trolamine salicylate [WHO-DD]
Common Name English
TRIETHANOLAMINE, SALICYLATE
Systematic Name English
NEO HELIOPAN TS
Brand Name English
Classification Tree Code System Code
CFR 21 CFR 352.20
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
CFR 21 CFR 352.10
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
Code System Code Type Description
SMS_ID
100000084670
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
DAILYMED
H8O4040BHD
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
NCI_THESAURUS
C84231
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID4047969
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
MESH
C032758
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
FDA UNII
H8O4040BHD
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
DRUG CENTRAL
4442
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
WIKIPEDIA
TROLAMINE SALICYLATE
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
MERCK INDEX
m11100
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY Merck Index
EVMPD
SUB04990MIG
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
PUBCHEM
25213
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
CAS
2174-16-5
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
DRUG BANK
DB11079
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107288
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
RXCUI
38866
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
218-531-3
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY